High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection

BMC Pharmacology and Toxicology, Jan 2006

Background The taxanes paclitaxel and docetaxel have traditionally been used in high doses every third week in the treatment of cancer. Lately there has been a trend towards giving weekly low doses to improve the therapeutic index. This article describes the development of high performance liquid chromatographic (HPLC) methods suitable for monitoring taxane levels in patients, focusing on patients receiving low-dose therapy. Methods Paclitaxel and docetaxel were extracted from human plasma by solid phase extraction, and detected by absorbance at 227 nm after separation by reversed phase high performance liquid chromatography. The methods were validated and their performance were tested using samples from patients receiving paclitaxel or docetaxel. Results The limits of quantitation were 1 nM for docetaxel and 1.2 nM for paclitaxel. For both compounds linearity was confirmed from the limit of quantitation up to 1000 nM in plasma. The recoveries ranged between 92% and 118% for docetaxel and between 76% and 104% for paclitaxel. Accuracy and precision were within international acceptance criteria, that is within ± 15%, except at the limit of quantitation where values within ± 20% are acceptable. Low-dose patients included in an on going clinical trial had a median docetaxel concentration of 2.8 nM at 72 hours post infusion. Patients receiving 100 mg/m2 of paclitaxel had a mean paclitaxel concentration of 21 nM 48 hours after the end of infusion. Conclusion We have developed an HPLC method using UV detection capable of quantifying 1 nM of docetaxel in plasma samples. The method should be useful for pharmacokinetic determinations at all relevant doses of docetaxel. Using a similar methodology paclitaxel can be quantified down to a concentration of 1.2 nM in plasma with acceptable accuracy and precision. We further demonstrate that the previously reported negative influence of Cremophor EL on assay performance may be overcome by degradation of the detergent by incubation with lipase.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.biomedcentral.com/content/pdf/1472-6904-6-2.pdf

High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection

BMC Clinical Pharmacology Technical advance High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection Anders Andersen 2 David J Warren 2 Paal F Brunsvig 1 Steinar Aamdal 0 Gunnar B Kristensen 3 Harald Olsen 2 0 Department of Clinical Research, The Norwegian Radium Hospital , N-0310 Oslo , Norway 1 Department of Medical Oncology, The Norwegian Radium Hospital , N-0310 Oslo , Norway 2 Central Laboratory, The Norwegian Radium Hospital , N-0310 Oslo , Norway 3 Department of Gynecologic Oncology, The Norwegian Radium Hospital , N-0310 Oslo , Norway Background: The taxanes paclitaxel and docetaxel have traditionally been used in high doses every third week in the treatment of cancer. Lately there has been a trend towards giving weekly low doses to improve the therapeutic index. This article describes the development of high performance liquid chromatographic (HPLC) methods suitable for monitoring taxane levels in patients, focusing on patients receiving low-dose therapy. Methods: Paclitaxel and docetaxel were extracted from human plasma by solid phase extraction, and detected by absorbance at 227 nm after separation by reversed phase high performance liquid chromatography. The methods were validated and their performance were tested using samples from patients receiving paclitaxel or docetaxel. Results: The limits of quantitation were 1 nM for docetaxel and 1.2 nM for paclitaxel. For both compounds linearity was confirmed from the limit of quantitation up to 1000 nM in plasma. The recoveries ranged between 92% and 118% for docetaxel and between 76% and 104% for paclitaxel. Accuracy and precision were within international acceptance criteria, that is within 15%, except at the limit of quantitation where values within 20% are acceptable. Low-dose patients included in an on going clinical trial had a median docetaxel concentration of 2.8 nM at 72 hours post infusion. Patients receiving 100 mg/m2 of paclitaxel had a mean paclitaxel concentration of 21 nM 48 hours after the end of infusion. Conclusion: We have developed an HPLC method using UV detection capable of quantifying 1 nM of docetaxel in plasma samples. The method should be useful for pharmacokinetic determinations at all relevant doses of docetaxel. Using a similar methodology paclitaxel can be quantified down to a concentration of 1.2 nM in plasma with acceptable accuracy and precision. We further demonstrate that the previously reported negative influence of Cremophor EL on assay performance may be overcome by degradation of the detergent by incubation with lipase. - Background Paclitaxel (figure 1a) was discovered in the early 1970's as being the active cytotoxic constituent in extracts of the bark of the yew Taxus Brevifolia. Paclitaxel had a unique mechanism of action, but the supply was limited and formulation of the compound for clinical use was difficult as paclitaxel is practically insoluble in water. Docetaxel (figure 1b), a semisynthetic analog of paclitaxel with higher aqueous solubility, was constructed from 10-deacetyl baccatin III about 10 years later. Several review articles on the clinical and preclinical pharmacokinetics of paclitaxel and docetaxel have been published [1-3]. Docetaxel for clinical use is currently formulated as a concentrate in polysorbate 80, and about 4 ml of this nonionic detergent is infused together with a standard dose (173 mg) of docetaxel. The plasma concentration of polysorbate 80 is about 0.1% during the infusion and the compound is rapidly cleared from plasma [4,5]. This is in contrast to Cremophor EL, the solvent for paclitaxel, where about 27 ml is infused together with a standard dose (303 mg), and the plasma concentration remains high (above 0.1%) for days due to a low volume of distribution (3 L/m2) and a long half-life (4080 h) [6-10]. Cremophor EL has been reported to have a negative influence on the reproducibility of paclitaxel determinations [11]. No such effects have been reported for polysorbate 80 and docetaxel. Numerous analytical methods for the taxanes have been published. Most of them rely on sample preparation by solid phase extraction followed by separation by HPLC and detection by absorbance at 225230 nm. The majority of methods for both paclitaxel and docetaxel are based on the principles for extraction and separation published by Willey et al. [12] in 1993, but also methods based on organic extraction are used [13-15]. Lately, mass spectrometry (MS) based methods with simplified sample preparations and limits of detections in the sub-nanomolar range have appeared [4,16-19]. The improved sensitivity has given new insight into the pharmacokinetics of the taxanes [20,21]. The method development presented here was started to support a dose escalation study with paclitaxel in patients with ovarian cancer. As we lacked an MS-instrument, the detection utilized UV absorbance. Later on the de (...truncated)


This is a preview of a remote PDF: http://www.biomedcentral.com/content/pdf/1472-6904-6-2.pdf

Anders Andersen, David J Warren, Paal F Brunsvig, Steinar Aamdal, Gunnar B Kristensen, Harald Olsen. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection, BMC Pharmacology and Toxicology, 2006, pp. 2, 6, DOI: 10.1186/1472-6904-6-2